Sponsor Overview
Explore verified public information about NS Pharma, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 2 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“NS Pharma, Inc. (NS Pharma) supports Expanded Access programs when we have substantial scientific evidence to support both the safety and the efficacy of investigational therapies based on the results from clinical studies. At this time, NS Pharma does not have unapproved, investigational therapies available for Expanded Access. This policy is not applied to NS Pharma’s approved drug, Viltepso®.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Muscular Dystrophy, Duchenne, DMD
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Single-Patient Expanded Access Policies and Criteria - If a treating physician believes that expanded access may be the only option for a patient, the physician should contact NS Pharma to make a formal request on behalf of a patient. Physicians may contact Early Access Care by emailing nspharma.expandedaccess@earlyaccesscare.com . We may request additional information to assist with patient eligibility for an investigational medication. Available Therapies via Single-Patient EA Viltolarsen Expanded Access for Duchenne Muscular Dystrophy - Confirmed DMD mutation in the dystrophin gene that is amenable to skipping of exon 53 Disease/Category-Specific EA Policies/Criteria https://www.earlyaccesscare.com/companies/ns+pharma+inc./viltolarsen
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.